Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DELCATH SYSTEMS, INC.DCTH · Entity 5387 | Chief Financial Officer | March 06, 2026 | March 06, 2026 |
| Vericel CorpVCEL · Entity 4481 | VP and Corporate Controller | September 30, 2020 | October 02, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DELCATH SYSTEMS, INC.
Report date March 06, 2026 · Filed March 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 77,018 |
Reported balance
After 2026-03-06 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-03-06 · Purchase · Acquired 5,533 · Balance 77,018 F1: Includes an aggregate of 10,433 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes an aggregate of 10,433 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan.
Vericel Corp
Report date September 30, 2020 · Filed October 02, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,440 |
Reported balance
Holding disclosure · report date 2020-09-30 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 3,440 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.65 · Expires 2027-05-22 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-09-30 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: These options began vesting on March 17, 2017 and shall vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.51 · Expires 2029-03-20 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-09-30 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F2: These options began vesting on March 20, 2019 and shall vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.51 · Expires 2029-03-20 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-09-30 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F2: These options began vesting on March 20, 2019 and shall vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.10 · Expires 2028-03-21 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-09-30 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance Not disclosed F3: These options began vesting on March 21, 2018 and shall vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.25 · Expires 2030-03-18 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-09-30 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance Not disclosed F4: These options began vesting on March 18, 2020 and shall vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.25 · Expires 2030-03-18 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-09-30 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance Not disclosed F4: These options began vesting on March 18, 2020 and shall vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.61 · Expires 2026-03-18 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-09-30 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance Not disclosed F5: These options began vesting on March 18, 2016 and shall vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.90 · Expires 2027-03-17 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-09-30 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance Not disclosed F1: These options began vesting on March 17, 2017 and shall vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.63 · Expires 2025-02-11 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-09-30 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance Not disclosed F6: These options, representing the right to purchase 20,000 shares, became exercisable on February 11, 2016, the first anniversary of the date of grant, with 25% vesting and the remaining 75% vesting in equal quarterly installments over three years thereafter. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-09-30 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance Not disclosed F7: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F8: These RSUs vest in four annual installments. The first installment of RSUs vested on March 20, 2020 and are shown in the holdings reported in Table I. The remaining 1,500 RSUs will vest in annual installments on March 20, 2021, March 20, 2022, and March 20, 2023, respectively. F9: No expiration date for this type of award. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-09-30 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance Not disclosed F7: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F10: These RSUs vest in four annual installments with 500 RSUs vesting on March 18, 2021, March 18, 2022, March 18, 2023 and March 18, 2024, respectively. F9: No expiration date for this type of award. |
Filing footnotes · ownership attribution and instrument terms
F1: These options began vesting on March 17, 2017 and shall vest and become exercisable in equal quarterly installments over the course of the following four (4) year period.
F2: These options began vesting on March 20, 2019 and shall vest and become exercisable in equal quarterly installments over the course of the following four (4) year period.
F3: These options began vesting on March 21, 2018 and shall vest and become exercisable in equal quarterly installments over the course of the following four (4) year period.
F4: These options began vesting on March 18, 2020 and shall vest and become exercisable in equal quarterly installments over the course of the following four (4) year period.
F5: These options began vesting on March 18, 2016 and shall vest and become exercisable in equal quarterly installments over the course of the following four (4) year period.
F6: These options, representing the right to purchase 20,000 shares, became exercisable on February 11, 2016, the first anniversary of the date of grant, with 25% vesting and the remaining 75% vesting in equal quarterly installments over three years thereafter.
F7: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation.
F8: These RSUs vest in four annual installments. The first installment of RSUs vested on March 20, 2020 and are shown in the holdings reported in Table I. The remaining 1,500 RSUs will vest in annual installments on March 20, 2021, March 20, 2022, and March 20, 2023, respectively.
F9: No expiration date for this type of award.
F10: These RSUs vest in four annual installments with 500 RSUs vesting on March 18, 2021, March 18, 2022, March 18, 2023 and March 18, 2024, respectively.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 06, 2026 Filed Mar 6, 2026 21:22 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | PurchaseCommon Stock | 5,533 | $9.04 | $50,018.32 |
DisclosureSEC source: 0001824817-26-000006 · form4-03062026_090318.xml · nonDerivative · entry 1 Pennell Sandra · CIK 0001824817 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,018 F1 · balance_after: Includes an aggregate of 10,433 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 02:30 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | GrantRestricted Stock Units · Derivative | 28,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001824817-26-000003 · form4-02182026_090207.xml · derivative · entry 2 Pennell Sandra · CIK 0001824817 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,250 Underlying: Common Stock · 28,250 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: Represents an RSU award, one-third of which shall vest on February 17, 2027 with the remaining 2/3 two-thirds of the RSUs vesting in equal annual installments over the following two years. The vesting of the RSUs is subject to the Reporting Person's continuous service through each such vesting date. F3 · derivative.expiration_date: Represents an RSU award, one-third of which shall vest on February 17, 2027 with the remaining 2/3 two-thirds of the RSUs vesting in equal annual installments over the following two years. The vesting of the RSUs is subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 02:30 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | GrantStock Option (Right to Buy) · Derivative | 56,500 | $0.00 Strike: $9.40 | $0.00 |
DisclosureSEC source: 0001824817-26-000003 · form4-02182026_090207.xml · derivative · entry 1 Pennell Sandra · CIK 0001824817 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,500 Underlying: Common Stock · 56,500 shares Expires 2036-02-17 F1 · derivative.exercise_date: The option will vest and become exercisable at the rate of one-thirty-sixth (1/36th) per month with the first such vesting to occur on February 17, 2026 and monthly thereafter for so long as the reporting person remains an employee of Delcath Systems, Inc. (and subject to the terms and conditions of the Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan, as amended). Read SEC document |
| February 07, 2025 Filed Feb 8, 2025 00:18 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | GrantStock Option (Right to Buy) · Derivative | 113,000 | $0.00 Strike: $16.25 | $0.00 |
DisclosureSEC source: 0001415889-25-003408 · form4-02082025_120244.xml · derivative · entry 1 Pennell Sandra · CIK 0001824817 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,000 Underlying: Common Stock · 113,000 shares Expires 2035-02-07 F1 · derivative.exercise_date: The option will vest and become exercisable at the rate of one-thirty-sixth (1/36th) per month with the first such vesting to occur on February 7, 2025 and monthly thereafter for so long as the reporting person remains an employee of Delcath Systems, Inc. (and subject to the terms and conditions of the Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan, as amended). Read SEC document |
| March 19, 2024 Filed Mar 19, 2024 20:59 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | GrantCommon Stock | 26,881 | $3.72 | $99,997.32 |
DisclosureSEC source: 0001415889-24-008582 · form4-03192024_080349.xml · nonDerivative · entry 1 Pennell Sandra · CIK 0001824817 · SVP OF FINANCE, PFO AND PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,052 F1 · balance_after: Includes 4,171 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:44 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | GrantStock Option (Right to Buy) · Derivative | 100,500 | $0.00 Strike: $4.78 | $0.00 |
DisclosureSEC source: 0001415889-24-003760 · form4-02142024_090251.xml · derivative · entry 1 Pennell Sandra · CIK 0001824817 · SVP OF FINANCE, PFO AND PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,500 Underlying: Common Stock · 100,500 shares Expires 2034-02-12 F1 · derivative.exercise_date: The option will vest and become exercisable at the rate of one-thirty-sixth (1/36th) per month with the first such vesting to occur on February 12, 2024 and monthly thereafter for so long as the reporting person remains an employee of Delcath Systems, Inc. (and subject to the terms and conditions of the Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan, as amended). Read SEC document |
| November 17, 2023 Filed Nov 21, 2023 12:42 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | PurchaseCommon Stock | 30,000 | $2.43 | $72,900.00 |
DisclosureSEC source: 0001209191-23-056187 · doc4.xml · nonDerivative · entry 1 Pennell Sandra · CIK 0001824817 · SVP of Finance, PFO and PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.05 to $2.45 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| June 12, 2023 Filed Jun 22, 2023 01:22 UTC | DELCATH SYSTEMS, INC. DCTH · Entity 5387 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0000899243-23-016202 · doc4.xml · derivative · entry 1 Pennell Sandra · CIK 0001824817 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-06-12 F1 · derivative.exercise_date: One-third (1/3rd) of the shares subject to the option shall vest on June 1, 2024, with the remaining shares vesting in equal monthly installments over the following two years thereafter, for so long as the reporting person remains an employee of Delcath Systems, Inc. The option is also subject to acceleration under certain circumstances. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.